ArticleJournal of clinical laboratory analysis2025
Candidate Biomarkers Associated With Circulating Tumor Cell Status in Metastatic Colorectal Cancer.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) ranks as the third most prevalent cancer worldwide. Recent studies suggest the promising potential of microRNAs (miRNA) in predicting the status of circulating tumor cells (CTC), and their combined analyses could pave the way for significant advancements in assessing the risk of metastatic cancer. Here, we investigate the circulating miRNA signatures associated with CTC status in metastatic CRC (mCRC).
methodsThe CTC status of mCRC patients was assessed using AdnaTest ColonCancer technology, which detects tumor cells using an immunomagnetic approach and characterizes them based on colon-specific surface markers. The miRNA profiles were analyzed using the Agilent miRNA microarray in 8 CTC-positive, 8 CTC-negative, and eight healthy individuals. The functional implications of dysregulated miRNAs and their interactions with target mRNAs, TFs, and lncRNAs were determined through a comprehensive in silico analysis. Candidate miRNAs that were differentially expressed in CTC-positive and CTC-negative groups, which have prior evidence for their role in CRC biology, were validated using qPCR.
resultsWe identified two groups of dysregulated miRNAs associated with CTC status and multiple candidate biomarkers in suggested miRNA regulatory networks. Three miRNAs (hsa-miR-199a-5p, hsa-miR-326, hsa-miR-500b-5p), which were downregulated in the CTC-positive group compared to the CTC-negative group, were confirmed by qPCR and prioritized as candidate predictors of CTC status in mCRC.
conclusionOur findings suggest biomarker candidates that can be used to predict CTC status in individuals with mCRC. This might also provide new insights into new translational medicine applications in the management of mCRC through miRNA-based CRC-associated CTC detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.